MetaCap

Prestige Consumer Healthcare (PBH) vs Xencor (XNCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xencor (XNCR) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 109.6% versus a loss of 16.5%. Over five years, XNCR leads with a -6.2% price change compared with -12.0% for PBH. Xencor is the larger company by market cap ($2.50 billion vs $2.35 billion), about 1.1 times the size.

Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus -73.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PBH-16.48%XNCR+109.58%
+161%+59%-44%
Nov 21, 20251 yearNov 20, 2026
PBH-14.81%XNCR-9.77%
+60%-14%-87%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PBH versus XNCR key metrics
MetricPBHXNCR
Share price$49.63$33.26
Market cap$2.35B$2.50B
1-day change+0.06%-2.21%
YTD return-19.55%+117.24%
1-year return-16.48%+109.58%
5-year return-12.02%-6.15%
P/E ratio (TTM)15.32—
Forward P/E9.76—
EPS (TTM)$3.24$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.09B$125.58M
Revenue growth (YoY)-4.31%+13.65%
Net income (latest FY)$190.30M$-91.92M
Gross margin54.71%—
Operating margin28.42%-141.35%
Net margin17.48%-73.20%
52-week high$71.07$40.60
52-week low$41.77$10.38
Distance from 52-week high-30.17%-18.08%
Analyst consensusbuystrong_buy
Avg. price target upside+33.39%+27.78%
Average volume583.25K1.54M
Shares outstanding47.40M75.04M
Employees890260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XNCR has outperformed PBH by 126.1 percentage points over the past year.
  • Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus -73.2 cents for Xencor.
  • Xencor grew revenue faster in its latest fiscal year (+13.65% vs -4.31%).

About Prestige Consumer Healthcare

PBH stock →

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees

About Xencor

XNCR stock →

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

PBH vs XNCR FAQ

Which is bigger, Prestige Consumer Healthcare or Xencor?

Xencor (XNCR) is larger, with a market capitalization of $2.50B compared with $2.35B for Prestige Consumer Healthcare (PBH).

Which stock has performed better over the past year, PBH or XNCR?

XNCR returned +109.58% over the past 12 months, compared with -16.48% for PBH (price return, excluding dividends). Past performance does not predict future results.

Are Prestige Consumer Healthcare and Xencor in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons